Business Context and Reporting Period
This Form 8-K is filed by OncoGenex Pharmaceuticals, Inc. (not Achieve Life Sciences, Inc., as indicated in the metadata) with a report date of December 24, 2009. The filing addresses Item 5.02 regarding the compensatory arrangements of certain officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It solely discloses specific cash bonus awards totaling approximately CDN $190,500 and U.S. $108,000 to three executive officers.
Material Changes
Effective December 24, 2009, the Company awarded short-term cash bonuses under its Short Term Incentive Awards Program to the following executives:
- Scott Cormack: CDN $138,000
- Steve Anderson: CDN $52,500
- Cindy Jacobs: U.S. $108,000
The Company anticipates paying these awards on or about December 31, 2009.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies beyond the immediate execution of the bonus program.
Investor Verification Checklist
- Verify the total cash outflow impact of the bonuses (approx. $298,500 USD equivalent) on the company's year-end liquidity.
- Confirm the performance criteria met to trigger these specific short-term incentive awards.
- Check subsequent filings to ensure the bonuses were paid as anticipated by December 31, 2009.